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Vascular endothelial growth factor (VEGF) is a potent
angiogenic factor that maintains the glomerular and
peritubular capillary (PTC) network in the kidney. The soluble
form of the VEGF receptor-1 (soluble fms-like tyrosine kinase
1 (sFlt-1)) is known to regulate VEGF activity by binding VEGF
in the circulation. We hypothesized that VEGF may be
beneficial for maintaining glomerular filtration barrier and
vascular network in rats with progressive glomerulonephritis
(GN). For blockade of VEGF activity in vivo, rats were
transfected twice with plasmid DNA encoding the murine
sFlt-1 gene into femoral muscle 3 days before and 2 weeks
after the induction of antiglomerular basement membrane
antibody-induced GN. Inhibition of VEGF with sFlt-1 resulted
in massive urinary protein excretion, concomitantly with
downregulated expression of nephrin in nephritic rats.
Further, blockade of VEGF induced mild proteinuria in normal
rats. Administration of sFlt-1 affected neither the infiltration
of macrophages nor crescentic formation. In contrast,
treatment of sFlt-1 accelerated the progression of
glomerulosclerosis and interstitial fibrosis accompanied with
renal dysfunction and PTC loss at day 56. VEGF may play a
role in maintaining the podocyte function as well as renal
vasculature, thereby protecting glomeruli and interstitium
from progressive renal insults.
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Vascular endothelial growth factor (VEGF) is a potent
angiogenic factor that induces endothelial cell migration,
growth, differentiation, and regeneration through its recep-
tors, vascular endothelial growth factor receptor (VEGFR)-1
(Flt-1) and VEGFR-2 (KDR/Flk-1).1 In kidney, VEGF is
abundantly expressed in glomerular epithelial cells (podo-
cytes) and tubular epithelial cells, whereas the glomerular and
peritubular capillary (PTC) endothelial cells express cognate
VEGF receptors.2–4 The importance of VEGF in kidney is
evidenced by the fact that deficiency in VEGF selectively in
the podocytes showed impaired glomerular capillary forma-
tion owing to a loss of endothelial cells in mice,5 and
antagonizing circulating VEGF caused glomerular endo-
theliosis in pregnant rats, which is also noted in human
pre-eclampsia.6
In addition to the impacts of VEGF on endothelial cells,
physiological levels of VEGF are pivotal for maintaining
glomerular filtration barrier. In this regard, Sugimoto et al.
reported that anti-VEGF antibodies and soluble VEGF
receptor 1 (soluble fms-like tyrosine kinase 1 (sFlt-1)), which
inhibit VEGF activity by directly sequestering VEGF and
by functioning as a dominant-negative inhibitor against
VEGF receptors,7 respectively, induced proteinuria associated
with podocyte dysfunction in normal kidneys.8 Recent
reports from human clinical cancer trials using anti-VEGF
antibodies (Bevacizumab) suggest that proteinuria may be
associated with treatment protocols.9–11
Therefore, we hypothesized in this study that VEGF may
be responsible for maintaining the glomerular filtration
barrier and vascular network in rats with progressive glome-
rulonephritis (GN). Molecular and pathological mechanisms
involved in the increased levels of urinary protein, electron
microscopic findings, and the expression of slit diaphragm-
associated molecules were examined. Further, the effect of
inhibition of VEGF on podocyte-associated molecules was
examined. The present study shows that blockade of VEGF
activity by transfection of the plasmid DNA encoding sFlt-1
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gene in femoral muscles resulted in massive urinary protein
excretion, concomitantly with downregulated expression
of nephrin, which is one of the major glomerular slit
diaphragm-associated molecules,12 in diseased glomeruli.
Treatment with sFlt-1 affected the progression of glomerulo-
sclerosis and interstitial fibrosis, resulting in renal dysfunc-
tion. These results suggest that VEGF may play a role in main-
taining the podocyte function as well as renal vasculature,
thereby regulating urinary protein excretion and protecting
glomeruli and interstitium from progressive insults.
RESULTS
Expression of sFlt-1
Muscle fibers positive for sFlt-1 were observed in femoral
muscles from the sFlt-1 gene-transfected rats 6 days after
disease induction (Figure 1a). In contrast, sFlt-1 protein was
not detected in the muscles from the empty plasmid-treated
rats (Figure 1b). Further, reverse transcription-polymerase
chain reaction (RT-PCR) analysis of muscle tissue for sFlt-1
mRNA showed that sFlt-1 mRNA was expressed at the injec-
ted sites in sFlt-1-treated rats (Figure 1c). Finally, urinary
levels of sFlt-1 increased at day 6 in rats treated with sFlt-1
compared with those from vehicle-treated rats (Figure 1d),
and remained elevated for at least 14 days (data not shown).
Histopathological studies
Semiquantitative evaluation of deposition showed no signi-
ficant difference in the deposition of rabbit immuno-
globulin (Ig)G, rat IgG, or rat C3 between glomeruli from
rats administered sFlt-1 gene or empty plasmid only (data
not shown). These results suggest that induction of GN was
equivalent in the two groups.
Glomerular lesions showed endocapillary proliferation,
severe necrotizing lesions, and crescentic formation at day 6.
Numbers of ED-1-, proliferating cell nuclear antigen-,
and CD8-positive cells did not significantly differ by the
administration of sFlt-1 gene at day 6. Similarly, there was
no significant difference between sFlt-1- and vehicle-treated
rats in formation of crescentic lesions and the number of
total glomerular cells at day 6 (Table 1).
Vehicle-treated nephritic animals showed a marked degree
of glomerulosclerosis, as well as interstitial fibrosis at day 56
(Figure 2a–d). sFlt-1-treated rats showed significantly more
glomerulosclerosis and interstitial fibrosis at day 56.
Effects of VEGF blockade on urinary protein excretion
and renal function
Ten normal untreated rats excreted minute amounts of
protein in the urine. Blockade of VEGF-induced mild
proteinuria by day 6 in six normal rats without anti-GBM
serum, which was maintained for 28 days, but returned
to nearly normal levels at day 56 (Figure 3). In contrast, all
nephritic rats injected with empty plasmid excreted markedly
elevated amounts of protein in the urine at days 6, 14, and 56.
The administration of sFlt-1 gene significantly increased
proteinuria at days 14 and 56 compared with vehicle-treated
rats (Figure 3). Nephritic rats with inhibition of VEGF
showed hypoproteinemia, evidenced by reduced serum total
protein levels and massive ascites at killing (Figure 4a). At day
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Figure 1 | sFlt-1 expression in femoral muscle. The expression of
sFlt-1 in skeletal muscles, where gene transfer was performed with
electroporation, was detected by an immunohistochemical method.
(a) Fibers positive for sFlt-1 were observed in the femoral muscle
from the plasmid DNA encoding sFlt-1-transfected rats 6 days after
induction of GN. (b) There was no staining for sFlt-1 in the muscles
from rats transfected with empty plasmid. sFlt-1 mRNA in muscles
was determined by RT-PCR analysis. (c) sFlt-1 mRNA was detected in
muscles 6 days after induction of GN, and barely detected 56 days
after induction of GN. (d) Urinary levels of sFlt-1 increased 6 days after
disease induction in sFlt-1-treated rats. Original magnification,  100.
*Po0.05 compared with rats transfected with empty plasmid.
Table 1 | Effects of inhibition of VEGF activity via sFlt-1 on
histopathological changes on day 6a
Normal Vehicle sFlt-1 P-valueb
Crescentic formation (%) 0 37.372.7 36.475.4 0.88
Total cell numberc 55.371.1 109.271.5 113.571.6 0.09
PCNA-positive cellsc 1.870.5 7.070.2 7.170.4 0.88
ED-1-positive cellsc 0.870.1 13.970.5 13.470.7 0.52
CD8-positive cellsc 0.270.02 1.970.1 1.970.1 0.89
Abbreviations: PCNA, proliferating cell nuclear antigen; sFlt-1, soluble fms-like
tyrosine kinase 1; VEGF, vascular endothelial growth factor.
aValues are given as mean7s.e.m. n=4 in normal group, n=5 in vehicle group, and
n=4 in sFlt-1 group.
bStatistical analyses are based on unpaired Student’s t-test and Kruskal–Wallis test.
cNumber of cells/glomerular cross-section.
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56, animals with empty plasmid developed renal dysfunction
as evidenced by increased blood urea nitrogen levels.
However, inhibition of VEGF by administration of sFlt-1
gene increased blood urea nitrogen levels (Figure 4b). Serum
creatinine levels in sFlt-1-treated rats tended to increase
compared with those in vehicle-treated rats at day 56, but the
difference was not statistically significant.
Effects of VEGF blockade on glomerular epithelial cells and
slit diaphragm-associated molecules
Epithelial foot processes tended to fuse in all tufts at day 6 in
diseased glomeruli from rats treated with empty plasmid
(Figure 5a; white arrow). In nephritic rats treated with sFlt-1,
more severe fusion of epithelial foot processes occurred, and
podocyte foot processes could be identified hardly (Figure 5b;
black arrow). Podocytes in normal kidneys had faint desmin
expression. In contrast, desmin was expressed by podocytes
in nephritic rats and its expression was increased in sFlt-1-
treated rats both at days 6 and 56 (Figure 5c and d).
mRNA expression of nephrin was specifically decreased by
the inhibition of VEGF (Figure 5e). Nephrin protein, evalu-
ated immunohistochemically in normal kidneys, was detec-
ted in a linear pattern along glomerular capillary walls
(Figure 5f). Compared with rats treated with empty plasmid
(Figure 5g), nephrin protein was reduced in sFlt-1-treated
rats (Figure 5h). Concomitantly, Western blot analysis for
nephrin protein revealed that nephrin was reduced in
nephritic rats and that the reduction was more severe in rats
treated with sFlt-1 (Figure 5i). In addition, nephrin was
faintly expressed in both sFlt-1- and empty plasmid-treated
rats at day 56.
In contrast to nephrin expression, expression of podocin,
podoplanin, and podocalyxin did not change by the treat-
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Figure 2 | VEGF inhibition accelerated glomerulosclerosis and
interstitial fibrosis. Progressive renal lesions exhibited (a, c)
glomerulosclerosis and (c, d) interstitial fibrosis in rats transfected
with empty plasmid at day 56. In contrast, sFlt-1 treatment
accelerated renal pathology. (c) Glomerulosclerosis and (d) interstitial
fibrosis were more prominent. Original magnification,  200.
*Po0.05 compared with rats transfected with empty plasmid.
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Figure 3 | Increased urinary protein excretion by inhibition of
VEGF activity. Treatment of normal rats with sFlt-1 induced mild
proteinuria, and its levels were maintained for 28 days and were
decreased by (’) day 56. *Po0.01 compared with a level of
proteinuria at day 0. Results from rats administered with (J) empty
plasmid and (K) sFlt-1. Administration of sFlt-1 markedly increased
proteinuria. #Po0.05 compared with rats transfected with empty
plasmid.
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Figure 4 | Decreased serum total protein levels and deterioration
of renal function by sFlt-1 treatment. (a) Serum total protein levels
were decreased in sFlt-1-treated rats at day 56. *Po0.05 compared
with normal rats. #Po0.05 compared with vehicle-treated rats.
(b) Rats treated with sFlt-1 developed renal dysfunction, evidenced by
increased blood urea nitrogen levels at day 56. *Po0.001 compared
with normal rats. #Po0.05 compared with vehicle-treated rats.
1988 Kidney International (2006) 69, 1986–1995
o r i g i n a l a r t i c l e A Hara et al.: Role of VEGF in rat crescentic glomerulonephritis
ment with sFlt-1 in either mRNA levels (Figure 6a–c) or
protein levels (Figure 6d–g).
Microvascular changes associated with blockade of VEGF
In normal kidneys, thrombomodulin (TM)-positive glome-
rular and PTC endothelial cells were preserved (Figure 7a).
Six days after disease induction, sFlt-1-treated rats (Figure 7c
and d) had more severe TM-positive glomerular endothelial
cell loss than that observed in rats injected with empty plasmid
(Figure 7b and d). sFlt-1-treated rats tended to have decreased
areas of TM-positive PTC endothelial cells compared with
rats injected with empty plasmid at day 6 (Figure 7e).
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Figure 5 | Effects of anti-GBM GN and sFlt-1 treatment on podocytes and nephrin. (a) Podocyte foot processes fused in all tufts at day 6 in
diseased glomeruli from rats transfected with empty plasmid. (b) sFlt-1 treatment accelerated fusion of podocyte foot processes. Original
magnification,  3000. (c) Expression of desmin at day 6 in diseased glomeruli from rats with empty plasmid. (d) Increased desmin expression
in podocytes was observed in sFlt-1-treated rats at days 6 and 56. Original magnification,  400. (e) mRNA expression of nephrin in normal and
diseased kidneys. Expression of nephrin mRNA was decreased in anti-GBM GN and further downregulated by sFlt-1 treatment. *Po0.05
compared with normal rats. #Po0.05 compared with vehicle-treated rats. Immunofluorescent microscopic findings of nephrin in (f) normal rats
and (g) rats with empty plasmid. Nephrin expression was reduced at day 6. (h) Nephrin expression was further reduced in sFlt-1-treated rats
compared with rats with empty plasmid at day 6. Original magnification,  200. (i) sFlt-1 treatment markedly downregulated nephrin in
diseased glomeruli as shown by Western blot analyses. Molecular markers are shown in the left lane. Data are representative of three
experiments.
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Expressions of VEGF and its receptors, Flk-1 and Flt-1, in
normal and diseased kidneys
mRNA expression of three isoforms of VEGF in kidneys was
reduced in crescentic GN, and was further reduced by the
inhibition of VEGF (Figure 8a and b). In addition, these three
isoforms of VEGF were only faintly expressed in both sFlt-1-
and empty plasmid-treated rats at day 56 (Figure 8a and b).
VEGF protein was detected on podocytes in normal kidneys
by immunohistochemistry (Figure 8c). Compared with rats
treated with empty plasmid (Figure 8d), sFlt-1-treated rats
had reduced VEGF protein at day 6 (Figure 8e). VEGF
receptor, Flk-1, was detected in all glomeruli and PTC
endothelial cells in normal rat (Figure 8f). Six days after
induction of nephritis, the area of glomerular and tubulo-
interstitial tissue expressions of Flk-1 was decreased com-
pared with normal rats (Figure 8g, h, l and m). At day 56,
Flk-1 expression in glomeruli and interstitium was reduced
via VEGF blockade (Figure 8l and m). Similarly, the
expression of Flt-1 in diseased kidneys was barely detectable,
whereas it was readily detected in podocytes in normal
kidneys (Figure 8i–k).
DISCUSSION
This study demonstrates that administration of sFlt-1, a
selective and potent inhibitor of VEGF, accelerates protein-
uria with massive ascites, glomerulosclerosis, and interstitial
fibrosis in rat crescentic GN, and is associated with loss of
a slit diaphragm-associated molecule, nephrin, and endo-
thelium. In this study, sFlt-1 gene transfected in femoral
muscles was expressed at injected sites at mRNA and protein
levels and was released to circulation, from which it
translocated to urinary space beyond the glomerular base-
ment membrane (GBM) in diseased kidneys.7,13 This study
suggests that VEGF in rats with crescentic GN may be
important for maintaining renal vasculature and preventing
proteinuria via regulation of nephrin, VEGF appears to
protect the kidney from renal insults.
Blockade of VEGF accelerated proteinuria and reduced
specifically nephrin. Nephrin, a product of the NPHS1 gene
whose mutations cause congenital nephrotic syndrome of
the Finnish type, is exclusively expressed by glomerular
podocytes within the kidney and is localized to the podo-
cyte slit diaphragm.12,14 Recently, it has been reported that
nephrin not only is a key slit diaphragm component but
also prevents podocyte apoptosis.15 Mice injected with anti-
VEGF antibody or sFlt-1 developed proteinuria accompanied
by disruption/loss of slit diaphragm and specific nephrin
downregulation.8 Therefore, one explanation for decreased
expression of podocyte-associated molecules is that as a
result of anti-GBM antibody-induced GN, podocyte damage
occurred and progressed, followed by decreased expression of
nephrin. Moreover, treatment with VEGF results in decreased
urinary protein excretion and renal dysfunction.16 Until now,
the beneficial effect of VEGF on podocytes was thought to
be mediated indirectly by improvement of glomerular
endothelial cell survival, because podocytes were not known
to express VEGF receptors. However, in addition to this
paracrine role of VEGF in the glomerulus, it is possible that
VEGF has an autocrine function through its tyrosine-kinase
receptor that is required for podocyte survival in vitro.15,17
The data suggest that VEGF maintains podocyte function
and survival by regulation of nephrin, possibly acting in an
autocrine and/or paracrine manner in the progressive disease.
VEGF expression was downregulated via sFlt-1 in this
particular model. A recent report demonstrated that signal-
ing through extracellular matrix proteins, in particular,
laminin and its receptor a3b1 integrin, which is highly
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Figure 6 | Effects of anti-GBM GN and sFlt-1 treatment on
podocyte-associated molecules. mRNA expression of (a) podocin,
(b) podocalyxin, and (c) podoplaninwas decreased by anti-GBM GN
and sFlt-1 treatment did not have impact on mRNA expression of
these three podocyte-associated molecules. *Po0.05 compared with
normal rats. (d) Immunofluorescent microscopic findings of podo-
calyxin in normal rats. (e) Podocalyxin expression was reduced at day
6 in nephritic rats transfected with empty plasmid, which was not
different from that in (f) sFlt-1-treated rats. Original magnification,
 200. (g) sFlt-1 treatment did not alter the podocalyxin expression
in diseased glomeruli revealed by Western blot analyses. Molecular
markers are shown in the left lane. Data are representative of three
experiments.
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expressed in podocytes regulates VEGF production in
cultured podocytes.18 Hence, downregulated VEGF in this
model, at least in part, is likely owing to the disturbance of
the GBM matrix–podocyte interaction by anti-GBM anti-
bodies. Further decrease in VEGF expression was observed by
VEGF blockade via sFlt-1 during the course of disease. This
might be explained by podocyte damage being augmented by
inhibition of VEGF activity.5,8,15,17 Therefore, downregulated
VEGF in this model might perpetuate further podocyte loss
and endothelial injury, thereby leading to glomerulosclerosis.
VEGF binds two related receptors, Flt-1 and KDR/Flk-1.1,3
In rat kidney, Flk-1 has been shown to be expressed in
glomerular and peritubular endothelial cells.3 However, Flt-1
expression is controversial. In the present study, Flk-1 was
locally expressed in glomerular and peritubular endothelial
cells and was diminished during the disease course, conco-
mitantly with progressive glomerular and PTC loss. Flt-1 was
detected on podocytes in normal glomeruli, but was barely
detected in diseased kidneys in this model. Therefore, Flk-1
appears to be the major mediator of endothelial cell mito-
genesis and survival as well as angiogenesis in a crescentic
GN, as reported previously.19,20 PTC loss contributes to the
etiology of the interstitial fibrosis by playing an essential role
in impaired blood flow in tubular cells and interstitial cells.
PTC loss may result from downregulated expression of VEGF
in progressive renal diseases directly affecting PTC loss via its
prosurvival effect on endothelial cells.19,21 PTC loss may also
be caused by filtered urinary proteins that lead to parenchymal
damage and, eventually, renal fibrosis and dysfunction.22
Therefore, PTC loss observed in sFlt-1-treated rats may play a
crucial role in the deterioration of renal function. Recently,
Flt-1 has been shown to be expressed on mesangial cells23 and
conditionally immortalized human podocyte cell line.17 In
addition, it is upregulated in certain disease models such as
diabetic, passive Heymann nephritis, and puromycin amino-
nucleoside nephrosis.3,24 Therefore, VEGF blockade via sFlt-1
accelerated the injury of endothelial cells as well as podocytes,
mainly through the inhibition of Flk-1.
Monocytes/macrophages participate in inflammatory
processes in crescentic GN. VEGF promotes monocyte
chemotaxis via a primary effect on the receptor Flt-1.25
In the present study, however, no significant effect of
VEGF inhibition on crescentic formation, ED-1-positive
macrophages, CD8-positive T-lymphocytes, or proliferating
cell nuclear antigen-positive cells in the glomeruli was seen at
day 6. These findings were consistent with the previous
report that VEGF had no effect on infiltration of neutrophils,
CD3-T lymphocytes, and ED-1-positive macrophages in the
Thy-1/habu-snake venom GN model.26 One plausible reason
is that downregulated VEGF could not induce migration and
activation of monocytes/macrophages, because VEGF-
mediated chemotaxis for monocytes/macrophages depends
on the dose and gradient of VEGF.25 Therefore, although
VEGF affects migration and activation of monocytes/
macrophages when upregulated, such as in aortic and
coronary vascular inflammation,7,13,25,27 the residual VEGF
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Figure 7 | VEGF inhibition accelerated glomerular and peritubular endothelial loss. (a) TM-positive endothelial cells were detected
ubiquitously along with glomerular and peritubular capillaries in normal rats. (b) TM-positive endothelial cells were reduced in rats transfected
with empty plasmid at day 6. (c) sFlt-1 treatment accelerated reduction of TM-positive endothelial cells at day 6. Original magnification,  400.
(d, e) Loss of TM-positive glomerular and peritubular endothelial cells was prominent by sFlt-1 treatment. *Po0.05 compared with normal rats.
#Po0.05 compared with vehicle-treated rats.
Kidney International (2006) 69, 1986–1995 1991
A Hara et al.: Role of VEGF in rat crescentic glomerulonephritis o r i g i n a l a r t i c l e
in this model might have no significant impact on mono-
cytes/macrophages compared with its effects on endothelial
and glomerular epithelial cells.
In conclusion, our study shows that VEGF plays a role in
maintaining podocyte function as well as renal vasculature,
thereby protecting glomeruli and interstitium from progres-
sive renal insults.
MATERIALS AND METHODS
Animals
Inbred male Wistar–Kyoto rats, purchased from Charles River Japan
Inc. (Atsugi, Kanagawa, Japan), aged 12 weeks were fed standard rat
chow and given free access to water under 24 h light control. All the
procedures used in the animal experiments complied with the
standards set out in the Guideline for the Care and Use of Laboratory
Animals in Takara-machi Campus of Kanazawa University.
Expression vector
The 3.3 kb mouse soluble Flt-1 gene, originally obtained from the
mouse lung library,28 was cloned into the BamH1 (50) and Not1 (30)
sites of the eukaryotic expression vector plasmid cDNA3.7
Preparation of anti-rat GBM antibodies
Rat GBM was prepared using the method of Krakower and
Greenspon.29.The preparation of anti-rat GBM antibodies was
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Figure 8 | Effects of anti-GBM GN and sFlt-1 treatment on expression of VEGF and VEGF receptors, Flt-1, and Flk-1. mRNA expression of
VEGF in normal and diseased kidneys. (a) Expression of VEGF mRNA was decreased in anti-GBM GN, and further downregulated by sFlt-1
treatment. Densitometric analysis of data in (a and b). Total expression of three isoforms of VEGF mRNA in each sample is presented as a ratio
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression in that sample. *Po0.001 compared with normal rats. #Po0.001
compared with vehicle-treated rats. (c) VEGF was detected in podocytes in normal kidneys. (d) In nephritic rats, VEGF expression was reduced,
and (e) was further decreased by sFlt-1 treatment at day 6. (f) Flk-1 was expressed in glomerular and peritubular endothelial cells. (g, l, and m)
Flk-1 expression was reduced in diseased kidneys, especially in glomeruli involved with crescentic lesions at day 6. (h, l, and m) Flk-1 expression
was more severely decreased in sFlt-1-treated rats. Flt-1 was detected on podocytes in (i) normal glomeruli and was hardly expressed in
diseased kidneys of both (j) vehicle-treated and (k) sFlt-1-treated rats. Original magnification,  400. *Po0.05 compared with normal rats.
#Po0.05 compared with vehicle-treated rats.
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described previously.30 Specificity was confirmed by in vitro indirect
immunofluorescence assays, using fluorescein isothiocyanate-
conjugated anti-rabbit IgG, on frozen sections of normal Wistar
rat kidneys. Sharp linear immunofluorescence was observed only
along the GBM.
Experimental design
Twenty male Wistar–Kyoto rats were injected intravenously with
0.1 ml of nephrotoxic serum at day 0. Nine of 20 rats received an
intramuscular injection of sFlt-1 plasmid (500 mg/150 ml phosphate-
buffered saline) into the femoral muscles with a 26-G needle 3 days
before injection of nephrotoxic serum, and five of nine rats received
another injection of the plasmid 2 weeks thereafter. To enhance
transgene expression, electroporation was performed at the injected
site immediately after injection as described previously.31,32 sFlt-1-
treated rats were killed at days 6 (four rats) or 56 (five rats), and
blood samples were collected. Muscle samples were obtained by
partial excision of the sFlt-1-injected sites at days 6 and 56. Urine
was collected 0, 6, 14, and 56 days after the nephrotoxic serum
injection. The remaining 11 nephritic rats injected with empty
plasmid with electroporation were also killed at days 6 (five rats) or
56 (six rats). As a control, urinary excretion of protein was measured
at days 6, 14, 21, 28, and 56 in six normal rats transfected with sFlt-1
plasmid with electroporation. Levels of urinary protein excretion
were determined at days 6, 14, and 56 in 10 normal untreated rats to
establish normal values.
Expression of sFlt-1
The expression of sFlt-1 in skeletal muscle, which was fixed in 10%
formalin followed by embedding in paraffin, was detected by
immunohistochemistry using peroxidase-labeled polymer conju-
gated to goat anti-rabbit IgG (Envision System; DAKO Co.,
Carpinteria, CA, USA) and anti-Flt-1 antibodies (C-17; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) 6 days after disease
induction.31 Moreover, Flt-1 mRNA in femoral muscle was detected
using RT-PCR. In brief, the cDNA was reverse-transcribed from
1 mg total RNA using a RT-PCR kit (Takara Shuzo, Tokyo, Japan).
The cDNA product was amplified by PCR. Primers for mouse sFlt-1
(50-GGTGCCCGCTCTTTG-30 (sense); 50-TGTCTCAGTGGGGATT
GC-30 (antisense)) were used to detect sFlt-1.33 The housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase was used for PCR
controls.
Urinary sFlt-1 measurements
The commercially available enzyme-linked immunosorbent assay
kits (R&D Systems, Minneapolis, MN, USA) were used to measure
mouse urinary sFlt-1 according to the manufacturer’s instructions.
Histopathological studies
A portion of renal tissue was prepared as reported previously.30 The
total number of cells and number of glomeruli with crescentic
formation were measured and expressed as described previously.30
The extent of glomerular sclerosis was expressed as a percentage of
the periodic acid-methanamine silver-positive area/whole glome-
rular area as described previously.34 Each area was measured by a
computer-aided manipulation using Mac Scope version 6.02
(Mitani Shoji Co., Ltd, Fukui, Japan). The extent of interstitial
fibrosis, expressed as blue in Mallory–azan staining, was evaluated as
reported previously.32,35
In an indirect immunoperoxidase staining, endothelial cells
were detected with mouse anti-TM monoclonal antibody (141C01;
NeoMarkers, Fremont, CA, USA), injured podocytes with mouse
anti-desmin monoclonal antibody (D33; DAKO Co.), VEGFR-1
with goat anti-Flt-1 polyclonal antibodies (C-17; Santa Cruz
Biotechnology), and VEGFR-2 with mouse anti-Flk-1 monoclonal
antibody (A-3; Santa Cruz Biotechnology). In each biopsy, TM-
and Flk-1-positive areas in glomeruli and tubulointerstitium
were identified and expressed in a similar manner as described
above, respectively.34,35
Another portion of renal tissue was frozen rapidly and
immunostained directly with fluorescein isothiocyanate-conjugated,
antiproliferating cell nuclear antigen (No. 033L245; Leinco Tech-
nologies Inc., St Louis, MO, USA) or indirectly with a mouse
monoclonal antibody against rat tissue monocytes and macro-
phages, ED1 (IgG1; BMA Biomedicals Ltd, Augst, Switzerland) or a
mouse monoclonal antibody against rat CD8 (IgG1; No. 0412;
Cedarlane, Hornby, Ontario, Canada). Positive cells were counted
on at least 50 randomly chosen glomeruli. Renal tissues obtained
from four normal Wistar–Kyoto rats were used as negative controls.
To evaluate the induction of GN, fluorescein isothiocyanate-conju-
gated anti-rabbit IgG (No. 38236; Organon Teknika Corporation,
Durham, NC, USA), fluorescein isothiocyanate-conjugated anti-rat
C3 (No. 38810; Organon Teknika Corporation), and fluorescein
isothiocyanate-conjugated anti-rat IgG (No. 38731; Organon
Teknika Corporation) were used.30
Detection of VEGF protein and its mRNA
To examine the production of VEGF in kidney before and after
disease induction, immunohistochemical analysis was performed on
paraffin-embedded tissue specimens with mouse anti-VEGF mono-
clonal antibody (C-1; Santa Cruz Biotechnology). In addition, to
determine transcripts of VEGF, RT-PCR was performed using
primers for VEGF (50-GACCCTGGTGGACATCTTCCAGGA-30
(sense); 50-GGTGAGAGGTCTAGTTCCCGA-30 (antisense)) with
expected sizes of 514, 462, and 330 bp for amplification of VEGF188,
VEGF 164, and VEGF 120, respectively.36
Detection of the glomerular epithelial slit
diaphragm-associated molecules and extent
of foot process effacement
Morphological changes of podocytes were examined by electron
microscopy as described previously (Hitachi H-600, Tokyo,
Japan).30 Next, the presence of nephrin was demonstrated
immunohistochemically in frozen tissue specimens with mouse
anti-rat nephrin monoclonal antibody 5-1-6, and that of podo-
calyxin with mouse anti-podocalyxin monoclonal antibody (4D5;
gift from Dr Masanori Hara).
mRNA expression of nephrin, podocin, and podocalyxin was
analyzed by real-time RT-PCR on isolated cortices of kidneys
from each group of rats. The cDNA was reverse-transcribed from
1 mg total RNA using SuperScript II RNase H reverse transcriptase
(Invitrogen, Carlsbad, CA, USA). Reverse transcription was
performed using the following parameters: 10 min at 251C, 30 min
at 481C, and 5 min at 951C. In real-time PCR experiments, the
Sequence Detection System (7900HT; Applied Biosystems, Foster
City, CA, USA) was used. Primers for nephrin (Rn00575235, Nphs1;
Applied Biosystems), podocin (Rn00709834, Nphs2; Applied
Biosystems), and podocalyxin (Rn00593804, Podxl; Applied Bio-
systems) were used. The housekeeping gene, b-actin (Rn00667869,
Actb; Applied Biosystems) was used for PCR controls. The reactions
were incubated at 951C for 10 min, followed by 40 cycles of 15 s at
951C, 10 s at 551C, and 20 s at 721C. mRNA expression of nephrin,
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podocin, and podocalyxin in each sample was finally described after
correction with b-actin expression. In addition, expression of
podoplanin mRNA was analyzed by RT-PCR. cDNA was reverse-
transcribed from 1 mg total RNA using a reverse transcription-PCR
kit (Takara Shuzo). Primers for podoplanin (forward: 50-GAGCG
TTTGGTTTCTGGGACTCA-30; reverse: 50-GGTGAGAGGTCTAGT
TCCCGA-30)37 were used. The housekeeping gene, glyceraldehyde-
3-phosphate dehydrogenase was used for PCR control. The reactions
were incubated at 941C for 3 min, followed by 35 cycles of 30 s
at 941C, 30 s at 581C, and 60 s at 721C.37 Scanner analysis was
examined as described previously.32,35
Western blot analysis
Isolated cortical portions of kidneys from each group were prepared
as described elsewhere. The protein concentration of each sample
was measured by Bradford Protein Assay kit (Bio-Rad Laboratories
Inc., Hercules, CA, USA). The homogenate was diluted with
Laemmli sample buffer (Bio-Rad Laboratories Inc.) and was boiled
for 5 min and cooled on ice. Ten micrograms of protein were
subjected to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and electroblotted onto a polyvinylidene difluoride
membrane (Bio-Rad Laboratories Inc.). The membrane was blocked
with bovine serum albumin-containing TBST buffer (20 mM Tris,
pH 7.6, 140 mM NaCl, and 0.1% Tween 20), and then incubated with
goat anti-nephrin polyclonal antibodies (N-20; Santa Cruz Bio-
technology)38 or rabbit anti-podocalyxin polyclonal antibodies
(KR064; Transgenic Co., Hyogo, Japan). To visualize the signals,
the membrane was incubated with biotinylated rabbit anti-goat
immunoglobulins (DAKO Co.) followed by streptavidin–horseradish
peroxidase complex (DAKO Co.) for nephrin or with peroxidase-
labeled polymer conjugated to goat anti-rabbit IgG (Envision
System; DAKO Co.) for podocalyxin.
Determination of urinary protein, blood urea nitrogen, serum
creatinine, and serum total protein concentrations
Urinary protein concentrations were determined as reported
previously.39 Urinary protein excretion was expressed as the ratio
of urinary protein to urinary creatinine. Blood urea nitrogen, serum
and urinary creatinine, and serum total protein levels were measured
using an automated analyzer (Hitachi, Tokyo, Japan) according to
the manufacturer’s instructions.
Statistical analyses
The mean and standard error were calculated on all parameters
determined in this study. Statistical analyses were performed using
the unpaired Student’s t-test and Kruskal–Wallis test. Values of
Po0.05 were considered statistically significant.
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